Trends & Perspectives

Changing the Face of Cancer Research

Christopher Ung, Vice President, Strategic Business & Operations, Oncology, at TMD, a Quintiles Central Laboratory, explains how advances in biomarker technology are ushering in a new era of cancer therapy development.

Find out more

Validated Biomarker Menu

A comprehensive menu of validated cell, fluid and tissue based biomarker assays.

Read more

Central Lab: Biomarker & Assay Development Services

Biomarker and Assay Development Services

We have capabilities in cell, fluid and tissue-based biomarkers from initial identification and qualification, validation and dissemination, through to production.

Assay Development Laboratory

We focus on the in-sourcing of new and emerging biomarkers relevant to your needs:

  • Elisa, Luminex and biochip technologies
  • Flow Cytometry and cell-based technologies
  • GC/MS and LC/MS Molecular Biology
  • Technology Transfers (i.e. Immunogenicity)

When developing assays, Quintiles offers:

  • Validation plans & reports
  • Sponsor approval and signatures
  • Writing the method SOP
  • Preparing a detailed technology transfer document (including instrument programming)
  • Training of the Clinical Lab Staff
  • Setting up and supplying in-house PT specimens (bi-yearly to quarterly)